2,115 results on '"Novartis AG -- Forecasts and trends"'
Search Results
2. Ocular melanoma Market Expected to rise, 2034 | Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline
3. Adult-onset Still Disease Market Expected to rise, 2034 | Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., expected to drive market
4. EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma
5. Graft-Versus-Host Disease Market on Track for Major Expansion by 2034, According to DelveInsight | CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharma, Pharmacyclics, Novartis
6. T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight
7. Hypoxic Ischemic Encephalopathy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., J&J
8. Chronic Heart Failure Therapeutics Market Size in the 7MM was ~ USD 8,000 Million in 2023, is expected to grow by 2034 | DelveInsight
9. Cystic Fibrosis Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed
10. Cryopyrin-associated Periodic Syndromes Market on Track for Major Expansion by 2034, According to DelveInsight | Amgen, Biovitrum, Novartis, Ventyx Biosciences
11. Alcoholic Hepatitis Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Durect Corporation, Novartis, Intercept Pharmaceuticals, Immuron Ltd
12. ANCA-associated Vasculitis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Amgen, GlaxoSmithKline, AstraZeneca, Chemocentryx, Staidson (Beijing) Biopharma, Novartis
13. Sarcoma Drugs Strategic Industry Research Report 2023-2024 & 2030, Competitive Profiles of 42 Players Including Amgen, Bayer, Eisai, Eli Lilly, Johnson and Johnson, Novartis, Pfizer Inc
14. Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain
15. Osteoarthritis Market expected to rise | Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis, Kolon Tissuegene, Paradigm
16. Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron
17. Myocardial Infarction Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharma, Eli Lilly and Company, Boehringer
18. KRAS Inhibitors Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines
19. Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight
20. Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
21. Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics
22. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics
23. Alzheimer's Drugs Market Report 2024, with Profiles of 10+ Companies Including AbbVie, Biogen, Daiichi Sankyo, Eisai, Eli Lilly, H. Lundbeck, Lupin, Merck, Novartis, Pfizer, Teva Pharmaceutical & More
24. Hemophagocytic Lymphohistiocytosis Market to Reach New Heights in Growth by 2034, DelveInsight Predict | Incyte, Novartis, Atara Biotherapeutics, Bellicum Pharma
25. 'Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments'
26. ANCA-associated Vasculitis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharma, Novartis
27. Axial Spondyloarthritis Market on Track for Major Expansion by 2034, According to DelveInsight | UCB Biopharma, Celgene, Novartis, Pfizer, Merck, Inmagene Biopharma, Galapagos NV, Kyowa Kirin Co
28. Global Cancer Therapy Market Size to grow at a CAGR of ~9% by 2030, Evaluates DelveInsight
29. CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight
30. Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron|Sanofi (Dupixent) and Genentech|Novartis (Xolair) Dominate the Market
31. Age-related Macular Degeneration (AMD) Drugs Market to Hit $17.37 Billion by 2029
32. Hypertrophic Cardiomyopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing
33. Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics
34. Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd
35. Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsight
36. Castrate-resistant Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, Asserts DelveInsight | Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis
37. Autoinjectors Market to Grow by USD 303.7 Billion (2024-2028) Driven by Rising Allergies and Need for Immediate Care- Technavio
38. Diabetic Kidney Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Mitsubishi Tanabe Pharma, Novartis, PhytoHealth Corporation, Eli Lilly and Company, BioStratum
39. IgA Nephropathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Vera Therapeutics, RemeGen Co., Ltd., Anthera Pharma, Chinook Therapeutic, Ionis Pharma
40. Global Cancer Monoclonal Antibodies Market to Cross ~USD 157 Billion Mark by 2030 | DelveInsight
41. Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight
42. BCMA-Targeted Therapies Market to Witness Upsurge in Growth During the Study Period (2020-2034) | DelveInsight
43. Rare Kidney Diseases Market Report 2024 to 2035, by Target Indications, Type of Molecule, Route of Administration and Key Geographies
44. Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca
45. Axial Spondyloarthritis (axSpA) Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | UCB Biopharma, Celgene, Novartis, Pfizer, Merck, Inmagene Biopharma, Galapagos NV
46. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio
47. U.S. Inflammatory Bowel Disease Treatment Market Trends Analysis Report 2024-2030 Featuring Biogen, Novartis, Eli Lilly & Co, UCB, Celltrion, Merck & Co, and Johnson & Johnson
48. Gene And Cell Therapies In Rare Disorder Market Size in the 7MM was ~USD 2000 Million in 2023, estimated DelveInsight
49. KRAS Inhibitors Market Forecast 2034: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight
50. Bone Metastasis Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | XGEVA (denosumab), XOFIGO (radium-223 dichloride), Cabozantinib, 9-ING-41, more
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.